Navigation Links
Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
Date:8/23/2010

rially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPM™, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA;
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... For Pfizer, a key success factor in bringing ... the condition that the drug was designed to treat. ... shift the nomenclature for the condition from "impotence" (with ... dysfunction" (more clinical-sounding) to "ED" (casual and conversationally appropriate). ...
... At MEDRAD, Inc., community outreach is a celebrated ... Day of Caring, a company-sponsored event where employees ... volunteering in their communities. (Logo: ... 1000 MEDRAD employees will participate in the event ...
Cached Medicine Technology:Using Internal Communications to Help Build a Credible External Message Regarding New Pharmaceutical Products 2MEDRAD Employees Demonstrate Longstanding Commitment to Community 2MEDRAD Employees Demonstrate Longstanding Commitment to Community 3
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
(Date:7/10/2014)... More than 200 experts on aggression, who research issues ... attend the 21st World Meeting of the International Society ... Hotel, July 15-19. , Georgia State University is hosting ... year on alternating continents. , "We are excited to ... different countries, which will help produce fresh ideas about ...
(Date:7/10/2014)... infant seemingly cured of HIV that was reported as a ... The New England Journal of Medicine last fallnow ... of not taking antiretroviral therapy without evidence of virus, according ... case. , "Certainly, this is a disappointing turn ... in the child,s care, and the HIV/AIDS research community," said ...
(Date:7/10/2014)... The benefits of medical imaging far outweigh the ... Right Way, with The Right Radiation Dose. However, overuse ... Mayo Clinic is leading a collaborative effort to ensure ... published online in the Journal of Patient Safety ... Joint Commission, the Intersociety Accreditation Commission, and the Centers ...
(Date:7/10/2014)... brain operates much the same whether active or at ... understanding of schizophrenia, bipolar disorder and other serious mental ... , In newly published research in the journal ... Center for Molecular and Behavioral Neuroscience, determined that the ... basically the same as that of a person performing ...
Breaking Medicine News(10 mins):Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:Working to loosen the grip of severe mental illness 2
... June 30 LifeSecure Insurance Company,(LifeSecure), a wholly-owned ... announced the executive appointment of Ron Hagen to ... sales executive with extensive knowledge of,the long term ... was,regional sales vice president, long term care sales ...
... Mesothelioma Center as a way for victims, or the ... get help,very honest advice & tailor made assistance at ... According to Americas Watchdog, "watching what happened to a ... help all Mesothelioma victims, with the best possible free ...
... in newborns undergoing painful procedures should be limited ... newborn screening test but not for intramuscular injections, ... In this double-blind, randomized controlled trial of 240 ... that "sucrose reduced overall pain in newborns when ...
... how much physical activity children need to boost their health and ... study published ahead of print in the Archives of Disease ... and only one in eight girls manage the recommended weekly amounts. ... of 113 boys and 99 girls from 54 different schools, all ...
... The cognitive strategies humans use to regulate emotions can ... a team of New York University and Rutgers University ... recent issue of the journal Nature Neuroscience , ... influence decision making. , Previous research has demonstrated ...
... 25, 2008 marks a revolutionary day in history for anybody who cares ... almost tantamount to July 4th, Independence Day, for Lung Cancer. For the ... voice, thanks to Senators Chuck Hagel, Dianne Feinstein and the tireless work ... Lung Cancer Alliance. , ...
Cached Medicine News:Health News:The Mesothelioma Victims Center Offers Victims Of Asbestos Related Cancer & Their Loved Ones The Most Comprehensive Free Service Especially For US Navy Veterans 2Health News:The Mesothelioma Victims Center Offers Victims Of Asbestos Related Cancer & Their Loved Ones The Most Comprehensive Free Service Especially For US Navy Veterans 3Health News:UK and US guidelines on kids' physical activity levels need rethinking 2Health News:NYU, Rutgers study shows how using mental strategies can alter the brain's reward circuitry 2Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 2Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 3Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 4
Inquire...
Inquire...
... Before TOPscan Dispensers used to only have two ... process the completed job at a wholesale lab, ... The alternative was to finish the order in ... additional offices required another edger, lens inventory, more ...
Inquire...
Medicine Products: